Trial Condition(s):

Venous Thromboembolism

Special Drug Use Investigation of Xarelto for Venous thromboembolism (VTE) (JPMS-XAR-VTE)

Bayer Identifier:

17522

ClinicalTrials.gov Identifier:

NCT02558465

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this investigation is to assess safety
and effectiveness of Xarelto under practice routine use
in VTE secondary prevention after acute DVT, focusing
on hemorrhagic-related AEs, recurrent venous
thromboembolism (PE/DVT), all-cause mortality.
This study is a company sponsored, one- arm
prospective cohort study with patients to whom
Rivaroxaban treatment for VTE (PE/DVT) has been
chosen.
The study includes a standard observation period (1
year) and an extension survey period (2 years, at the
longest).

Inclusion Criteria
- Patients who start rivaroxaban for VTE(pulmonary embolism, deep vein thrombosis) anticoagulation therapy.
Exclusion Criteria
- Patients who are contraindicated based on the product label and have already received Xarelto treatment.

Trial Summary

Enrollment Goal
2540
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many locations

Many locations, Japan

Status
Recruiting
 

Trial Design